TargetMol

WNK-IN-11-d3

Product Code:
 
TAR-T24046
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T24046-5mg5mg£571.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24046-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24046-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
WNK-IN-12 is an effective, selective, and orally active WNK1 kinase inhibitor.
CAS:
2123483-49-6
Formula:
C21H21Cl2N5OS
Molecular Weight:
465.41
Purity:
0.98
SMILES:
[2H]C([2H])([2H])Nc1nc(cs1)-c1cc(C(=O)N2CCN(Cc3ccc(Cl)cc3)CC2)c(Cl)cn1

References

1. Vorontsova I, Donaldson PJ, Kong Z, Wickremesinghe C, Lam L, Lim JC. The modulation of the phosphorylation status of NKCC1 in organ cultured bovine lenses: Implications for the regulation of fiber cell and overall lens volume. Exp Eye Res. 2017 Dec;165:164-174. doi: 10.1016/j.exer.2017.08.009. Epub 2017 Aug 14. PubMed PMID: 28818393. 2. AlAmri MA, Kadri H, Alderwick LJ, Simpkins NS, Mehellou Y. Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains. ChemMedChem. 2017 May 9;12(9):639-645. doi: 10.1002/cmdc.201700077. Epub 2017 Apr 12. PubMed PMID: 28371477. 3. Zhang J, Deng X, Kahle KT. Leveraging unique structural characteristics of WNK kinases to achieve therapeutic inhibition. Sci Signal. 2016 Oct 18;9(450):pe3. Review. PubMed PMID: 27811182. 4. Bhuiyan MIH, Song S, Yuan H, Begum G, Kofler J, Kahle KT, Yang SS, Lin SH, Alper SL, Subramanya AR, Sun D. WNK-Cab39-NKCC1 signaling increases the susceptibility to ischemic brain damage in hypertensive rats. J Cereb Blood Flow Metab. 2017 Aug;37(8):2780-2794. doi: 10.1177/0271678X16675368. Epub 2016 Jan 1. PubMed PMID: 27798271; PubMed Central PMCID: PMC5536788.